ECG analysis is a recommended component of each cardio-oncological evaluation, because malignant arrhythmias are frequent side effects of many cancer therapies (e.g., anthracyclines, small-molecule tyrosine kinase inhibitors, Bruton’s tyrosine kinase inhibitors, immune checkpoint inhibitors and B-Raf proto-oncogene serine/threonine-kinase (BRAF) inhibitors) [3,6,7,8]. This evidence concerns the gene BRAF and cancer.